[1]杨懿 牟云飞 任福强 黄鑫 王园.表皮生长因子受体酪氨酸激酶抑制剂用于非小细胞肺癌术后辅助治疗的心脏毒性回顾性分析[J].心血管病学进展,2022,(8):763-768.[doi:10.16806/j.cnki.issn.1004-3934.2022.08.023]
　YANG Yi,MU Yunfei,REN Fuqiang,et al.A Retrospective Analysis of EGFR-TKIs-Induced Cardiotoxicity in Postoperative Adjuvant Therapy for Non-Small Cell Lung Cancer[J].Advances in Cardiovascular Diseases,2022,(8):763-768.[doi:10.16806/j.cnki.issn.1004-3934.2022.08.023]
点击复制

表皮生长因子受体酪氨酸激酶抑制剂用于非小细胞肺癌术后辅助治疗的心脏毒性回顾性分析()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2022年8期
页码:
763-768
栏目:
论著
出版日期:
2022-08-25

文章信息/Info

Title:
A Retrospective Analysis of EGFR-TKIs-Induced Cardiotoxicity in Postoperative Adjuvant Therapy for Non-Small Cell Lung Cancer
作者:
杨懿1 牟云飞 2 任福强2 黄鑫2 王园2
(成都市第三人民医院胸外科, 西南交通大学附属医院 ,四川 成都 610031)
Author(s):
YANG Yi1;  MU Yunfei2; REN Fuqiang2;  HUANG Xin2;  WANG?Yuan2
(Department of Thoracic Surgery,The Third People,s Hospital of Chengdu,The Affiliated Hospital of Southwest Jiaotong University,Chengdu, 610031,Sichuan,China )?/html>
关键词:
表皮生长因子受体酪氨酸激酶抑制剂; 心脏毒性; 肌钙蛋白T; 脑钠肽; 左心室射血分数
Keywords:
arial;  helvetica;  sans-serif;  text-indent: 28px; ">Epidermal growth factor receptor tyrosine kinases inhibitors; Cardiotoxicity; Troponin T; Brain natriuretic peptide; Left ventricular ejection fraction
DOI:
10.16806/j.cnki.issn.1004-3934.2022.08.023
摘要:
目的 评估表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKIs）作为非小细胞肺（NSCLC）癌术后辅助治疗长期使用的心脏毒性。方法 收集本院自2019年1月—2020年6月，102例NSCLC术后使用EGFR-TKIs作为辅助治疗的患者的临床资料；包括服药前、服药1周、服药1个月、服药3个月、服药6个月和服药12个月各时间点的心率及Q-T间期改变、左心室射血分数（LVEF）、肌钙蛋白T（cTnT）及脑钠肽（BNP），评估使用EGFR-TKIs作为NSCLC术后辅助治疗的心脏毒性。结果 102例患者中有5例出现心脏毒性，其中有3例（2.94%）出现LVEF下降≥10%，另外2例（1.96%）出现cTnT及BNP异常升高，将与之相关的危险因素进一步做多因素Logistic回归分析，得出年龄≥70岁是NSCLC术后EGFR-TKIs辅助治疗心脏毒性的独立危险因素（OR=8.732，P=0.002）。结论 EGFR-TKIs作为NSCLC术后辅助治疗时心脏毒性发生率较低，年龄≥70岁是NSCLC术后EGFR-TKIs辅助治疗心脏毒性的独立危险因素。
Abstract:
Objective?#160To evaluate the cardiotoxicity of long-term use of epidermal growth factor receptor tyrosine kinases inhibitors（EGFR-TKIs）in postoperative adjuvant therapy (PAT) for non-small cell lung cancer (NSCLC).?ethods?#160We collected the clinical data of 102 NSCLC?atients treated with EGFR-TKIs for PAT from January 2019 to January 2021. The changes of heart rate and Q-T interval, left ventricular ejection fraction (LVEF), troponin T (cTnT) and brain natriuretic peptide?BNP) before treatment, 1 week, and 1, 3, 6, 12 months after treatment were analyzed to evaluate EGFR-TKI-induced cardiotoxicity.?esults?#160The?ardiotoxicity was found in 5 patients, of which the LVEF in 3 cases (2.94%) was decreased by≥10%, cTnT and BNP in another 2 (1.96%) were increased abnormally. Further multivariate Logistic regression analysis on related risk factors indicated that the age≥70 was an independent risk factor for EGFR-TKIs-induced cardiotoxicity in NSCLC?djuvant therapy after surgery (OR=8.732, P=0.002). Conclusion?#160The incidence rate of EGFR-TKIs-induced cardiotoxicity in postoperative NSCLC?s relatively low. In addition, age≥70 is an independent risk factor for EGFR-TKIs-induced cardiotoxicity in NSCLC?ostoperative adjuvant therapy.

参考文献/References:

[1].Lenneman CG,Sawyer DB. Cardio-Oncology:an update on cardiotoxicity of cancer-related treatment[J]. Circ Res,2016,118(6):1008-1020．
[2].Thavendiranathan P,Abdel-Qadir H,Fischer HD,et al. Breastcancer therapy-related cardiac dysfunction in adult women treated in routine clinical practice:a population-based cohort study[J]. J Clin Oncol,2016,34(19):2239-2246．
[3].Leong SL,Chaiyakunapruk N,Lee SWH. Antineoplastic-related cardiov-ascular toxicity:A systematic review and meta-analysis in Asia[J]. Crit Rev Oncol Hematol,2019,141:95-101．
[4].Belyi D,Nastina O,Sydorenko G,et al. The development of hypertension disease and ischemic heart disease in emergency workers of the chornodyl accidnet and influence on it conditions of being under radiation[J]. Probl Radiac Med R adiobiol,2019,24:350-366．
[5].[5] Zamorano JL,Lancellotti P,Rodriguez Mu?oz D,et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines:The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology(ESC)[J]. Eur Heart J,2016,37(36):2768-2801．
[6].[6] Motzer RJ,Hutson TE,Cella D,et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma[J]. N Engl J Med,2013,369(8):722-731.
[7].[7] Motzer RJ,Escudier B,Tomczak P,et al. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma:overall survival analysis and updated results from a randomised phase 3trial[J]. Lancet Oncol,2013,14(6):552-562.
[8].[8] Ewer MS,Tekumalla SH,Walding A,et al. Cardiac safety of osimertinib: a review of data[J]. Clinical Oncology,2020,39(4):328-337.
[9].[9] Vivekanandan S,Landau DB,Counsell N,et al. The Impact of cardiac radiation dosimetry on survival after radiation therapy for non-small cell lung cancer[J]. Int J Radiat Oncol Biol Phys,2017,99(1):51-60．
[10].[10] Fallah-Rad N,Lytwyn M,Fang T,et al. Delayed contrast enhancement cardiac magnetic resonance imaging in trastuzumab induced cardiomyopathy[J]. J Cardiovasc Magn Reson,2008,10(1):5.
[11].[11] Malachowska B,Tomasik B,Stawiski K,et al. Circulating microRNAs as biomaikers of radiation exposure: a systematic review and meta-analysis[J]. Int J Radiat Oncol Biol Phys,2020,106(2):390-402.
[12].[12] Wu YL,Tsuboi M,He J,et al. Osimertinib in resected EGFR-mutated non-small-cell lung cancer[J]. N Engl J Med,2020,383(18):1711-1723.
[13].[13] 安涛,赵雪梅,张宇辉. 靶向药物治疗所致心功能异常的防治[J]. 中国实用内科杂志,2018,38(7):596-598．

相似文献/References:

[1]祁小青 周蕾.肿瘤治疗所致Ⅰ型心脏损伤的防治[J].心血管病学进展,2020,(7):741.[doi:10.16806/j.cnki.issn.1004-3934.2020.07.017]
　QI Xiaoqing,ZHOU Lei.Prevention and Treatment of TypeCardiac Injury Caused by Cancer Treatment[J].Advances in Cardiovascular Diseases,2020,(8):741.[doi:10.16806/j.cnki.issn.1004-3934.2020.07.017]
[2]唐雨琦 关旭敏 方凤奇 刘基巍 夏云龙.吉西他滨引起心脏毒性的研究现状[J].心血管病学进展,2020,(9):895.[doi:10.16806/j.cnki.issn.1004-3934.2020.09.002]
　TANG Yuqi,GUAN Xumin,FANG Fengqi,et al.Cardiotoxicity Induced by Gemcitabine[J].Advances in Cardiovascular Diseases,2020,(8):895.[doi:10.16806/j.cnki.issn.1004-3934.2020.09.002]
[3]赵恒 谭琦 杜晓宇 谷泽慧 王亚帝.蒽环类药物致心脏毒性潜在的生物标志物研究[J].心血管病学进展,2022,(3):282.[doi:10.16806/j.cnki.issn.1004-3934.2022.03.000]
　ZHAO HengTAN QiDU XiaoyuGU ZehuiWANG Yadi.Potential Biomarkers of Anthracycline-Induced Cardiotoxicity[J].Advances in Cardiovascular Diseases,2022,(8):282.[doi:10.16806/j.cnki.issn.1004-3934.2022.03.000]
[4]古力尼尕尔·麦麦提吐尔孙 付真彦.肺癌靶向治疗药物EGFR-TKI与其心脏毒性的研究进展[J].心血管病学进展,2022,(2):128.[doi:10.16806/j.cnki.issn.1004-3934.2022.02.009]
　GULINIGAER·Maimaitituersun,FU Zhenyan.EGFR-TKI and Its Cardiotoxicity in Lung Cancer[J].Advances in Cardiovascular Diseases,2022,(8):128.[doi:10.16806/j.cnki.issn.1004-3934.2022.02.009]
[5]代虎威 王馨焱 李松珊 温泽宇 曾康 杨滨.免疫检查点抑制剂相关心肌炎的诊断及管理研究进展[J].心血管病学进展,2022,(10):937.[doi:10.16806/j.cnki.issn.1004-3934.2022.10.017]
　Immune Checkpoint Inhibitor-Associated Myocarditis.Diagnosis and Management of[J].Advances in Cardiovascular Diseases,2022,(8):937.[doi:10.16806/j.cnki.issn.1004-3934.2022.10.017]
[6]王鹏 王鑫 张瑶 张经泽 贺世豪 李瑾.内质网应激在阿霉素心脏毒性中作用的研究进展[J].心血管病学进展,2023,(4):341.[doi:10.16806/j.cnki.issn.1004-3934.2023.04.012]
　WANG Peng,WANG Xin,ZHANG Yao,et al.Role of Endoplasmic Reticulum Stress?n the Cardiotoxicity of Doxorubicin[J].Advances in Cardiovascular Diseases,2023,(8):341.[doi:10.16806/j.cnki.issn.1004-3934.2023.04.012]
[7]邓悦 周晓阳.免疫检查点抑制剂相关心脏毒性的临床特点及研究进展[J].心血管病学进展,2023,(10):905.[doi:10.16806/j.cnki.issn.1004-3934.2023.10.010]
　DENG YueZHOU Xiaoyang?/html>.Clinical Characteristics and Progress of?ardiac Toxicity Associated with Immune Checkpoint Inhibitors[J].Advances in Cardiovascular Diseases,2023,(8):905.[doi:10.16806/j.cnki.issn.1004-3934.2023.10.010]
[8]李登科 张伟 黄从新.SIRT1介导的信号通路在阿霉素诱导心脏毒性中的作用机制[J].心血管病学进展,2024,(3):257.[doi:10.16806/j.cnki.issn.1004-3934.2024.03.015]
　LI Dengke,ZHANG Wei,HUANG Congxin.The Mechanisms of SIRT1-Mediated Signal Pathway in Doxorubicin-Induced Cardiotoxicity[J].Advances in Cardiovascular Diseases,2024,(8):257.[doi:10.16806/j.cnki.issn.1004-3934.2024.03.015]
[9]赵 珂 陈晓姝 魏希进 张 娟 刘 杨 卞雨敬 袁 杰.铁死亡的调控机制及其在蒽环类药物心脏毒性中的研究进展[J].心血管病学进展,2024,(3):261.[doi:10.16806/j.cnki.issn.1004-3934.202.03.016]
　First Clinical Medical College,Shandong University of Traditional Chinese Medicine,Jinan 0000,et al.Regulatory Mechanism of Ferroptosis and Its Progress in Anthracycline-Induced Cardiotoxicity[J].Advances in Cardiovascular Diseases,2024,(8):261.[doi:10.16806/j.cnki.issn.1004-3934.202.03.016]

备注/Memo

备注/Memo:
基金项目：四川省科技厅项目（2022YFQ0086）；成都市卫生健康委项目（2021175）
通信作者：王园，E-mail：307346147@qq.com
更新日期/Last Update: 2022-10-08